Family Therapy Training and Implementation Platform (FTTIP) Supplement Study

March 2, 2023 updated by: Training and Implementation Associates

Family Therapy Training and Implementation Platform (FTTIP): An Innovative Web-based Tool for Long-term Practice Improvement Supplement Study

The goal of this observational study is to learn about therapists' and agency leaders' experience with evidenced based treatments and the Family Therapy Training and Implementation Platform (FTTIP).

The main questions it aims to answer are:

  1. What are the perceptions and experiences of the therapists about the process of learning and practicing specific Culturally Informed Flexible Family Based Treatment for Adolescents (CIFFTA) competencies from the platform?
  2. What are therapists' unique experiences related to implementation of the evidenced based treatment (EBT), delivery of competencies learned, and the application of EBT in a real-world context?
  3. What are agency leaders' experiences in facilitating EBTs at their agencies what are the barriers that can be addressed by the organizational readiness work?
  4. What is the experience of the entire agency with the platform, consultation process, perceived cost-benefit, and agency readiness?

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The supplement project will have multiple components that augment the parent study by collecting qualitative data that we can combine with the parent study's quantitative data to better understand the experiences of trainees and agency leaders with the platform.Twenty trainees (randomly selected from the 75 CIFFTA parent study trainees) and 16 agency leaders from the sample of the parent study will be included. The proposed supplement aims to: 1) gather perceptions and experiences of the trainees about the process of learning and practicing specific CIFFTA competencies from the platform (time 1 interview) and later, about their unique experiences related to implementation of the EBT, delivery of competencies learned, and the application of EBT in a real-world context (time 2); and 2) gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work (time 1), and later regarding their agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness (at time 2).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants will be selected from therapists and agency leaders that are already enrolled in the parent study (150 counselors and 30 agency leaders).

Description

Inclusion Criteria:

  • Bachelors level counselor with 2 years of experience or Master's level counselors and therapists who have not had family therapy training in the past year and who are broadly representative of the potential trainees in the general population, including educational background and job experience with different client populations (e.g., varied demographics and presenting problems).
  • All therapists must be actively providing treatment to youth and be willing to deliver the family intervention to at least one family during the project period
  • Therapists must be enrolled in the parent grant and be randomized to the FTTIP condition
  • Agency leaders must be enrolled in the parent grant study
  • To be included in the study, agency leaders must have the authority to allocate agency resources (e.g., giving trainees protected time to participate in training activities, allowing smaller caseloads as they begin implementation) and be willing to participate in agency readiness and implementation consultation.

Exclusion Criteria:

  • • We are not limiting inclusion of any group by sex/gender, race, and/or ethnicity

    • Agencies that are unwilling to participate in all study activities, that have nontraditional funding sources (e.g., totally charity funded), or that are so small they cannot assign sufficient counselors to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Therapists
20 therapists who were already trained will participate in a qualitative interview to gather perceptions and experiences of the therapists about the process of learning and practicing specific CIFFTA competencies from the therapy training platform (time 1 interview) and later, about their unique experiences related to implementation of the Evidenced Based Treatment (EBT), delivery of competencies learned, and the application of EBT in a real-world context (time 2).
Other: Qualitative Interview
Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
Agency leaders
16 agency leaders from the main study will participate in qualitative interviews to 2) gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work (time 1), and later regarding their agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness (at time 2).
Other: Qualitative Interview
Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
TIA Therapist Interview Timepoint 1
Time Frame: After 2 weeks given to complete a 20 hour training
Interview to assess perceptions and experiences of the therapists about the process of learning and practicing specific CIFFTA competencies from the platform
After 2 weeks given to complete a 20 hour training
TIA Therapist Interview Timepoint 2
Time Frame: After four months of the implementation of the treatment with a family
Interview to assess therapists' unique experiences related to implementation of the Evidenced Based Treatment, delivery of competencies learned, and the application of EBT in a real-world context
After four months of the implementation of the treatment with a family
TIA Agency leader Interview Timepoint 1
Time Frame: Prior to the start of training or implementation of therapists at the organization
Interview to gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work
Prior to the start of training or implementation of therapists at the organization
TIA Agency leader Interview Timepoint 2
Time Frame: After four months of treatment implementation at the organization
Interview to assess agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness
After four months of treatment implementation at the organization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Training and Implementation Associates

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2023

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2024

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 2, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 2, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 14, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 14, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 2, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 3R44MH115547-02S1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings